You are on Trendlyne United States. Click here to go to India website or make United States as your default
  1. MARKETS
  2. SECTOR : COMMERCIAL SERVICES & SUPPLIES
  3. INDUSTRY : MISCELLANEOUS COMMERCIAL SERVICES
  4. MURAL ONCOLOGY PLC

Mural Oncology plc XNAS: MURA

Mural Oncology plc Live Share Price Today, Share Analysis and Chart

Download real time

2.69 -0.01 (-0.37%)

43.25% Fall from 52W High

1.4M XNAS Volume

High vol.+gain this week

XNAS 21 Apr, 2025 5:30 PM (EDT)

Watchlist

Portfolio

Share

Mural Oncology plc Key Metrics

Select

Market Capitalization

Below industry Median
46.3

PE TTM

Negative PE TTM
-0.4

Price to Book

Low in industry
0.3

Institutional holding current Qtr %

Below industry Median
47

Net Profit Qtr Growth YoY %

Below industry Median
42.4

Net Profit TTM Growth %

Below industry Median
38

Piotroski Score

Low in industry
2

Rel Perf vs Sector quarter%

-27.4

ROE Annual %

Negative ROE Annual %
-63.6

RoA Annual %

Negative RoA Annual %
-54.6
All financials are in USD Million and price data in USD
VIEW MORE
Durability score
Not Eligible
-
Valuation Score
Expensive Valuation
15.2 / 100
Momentum Score
Technically Bearish
32.7 / 100
Analyst Price Target
No estimates available

11

S

10

W

0

O

3

T

SWOT Analysis

Check P/E Buy Sell Zone

This stock has negative PE


Mural Oncology plc Live Price Chart

Switch to TradingView
Fetching data ...

Forecaster - Analyst Share Price Target and Estimates

Revenue forecast

Created with Highcharts 7.2.2
Forecaster is a Premium Feature
You need to upgrade your subscription plan to access this feature
See what you get

Mural Oncology plc Stock Analysis

Mural Oncology plc stock analysis with key metrics, changes, and trends.

Mural Oncology plc MetricVALUECHANGE %TRENDANALYSIS
Annual Net Profit$128.51 M38.05%positive

Annual Net Profit rose 38.05% in the last year to $128.51 M. Its sector's average net profit growth for the last fiscal year was -17.35%.

Price to Earning Ratio-0.36-negative

Price to Earning Ratio is -0.36, which is negative.

Stock Price$2.69-24.65%negative

Stock Price fell 24.65% and underperformed its sector by 34.67% in the past year.

Quarterly Net profit$34.27 M42.43%positive

Quarterly Net profit rose 42.43% YoY to $34.27 M. Its sector's average net profit growth YoY for the quarter was -51.46%.

Debt to Equity Ratio0.06-positive

Debt to Equity Ratio of 0.06 is less than 1 and healthy. This implies that its assets are financed mainly through equity.

Return on Equity(ROE)-63.57 %-63.57%negative

Return on Equity(ROE) for the last financial year was -63.57%, less than 10%, indicating an inefficient use of shareholder's capital to generate profit.

Mutual Fund Holding11.41 %-0.16%negative

Mutual Fund Holding decreased by 0.16% in the last quarter to 11.41.

Institutional Holding47.03 %0%negative

Institutional Holding decreased by 0% in the last quarter to 47.03.

VIEW LESS


Loading data..

Mural Oncology plc - Company Profile

What does Mural Oncology plc do?

Mural Oncology PLC is a clinical-stage oncology company whose entire business is focused on discovering and developing immunotherapies that may meaningfully improve the lives of patients with cancer. By leveraging its core competencies in immune cell modulation and protein engineering, It has developed a portfolio of novel, investigational cytokine therapies designed to address areas of unmet need for patients with a variety of cancers. Its product candidate, Nemvaleukin is an investigational, engineered interleukin-2 cytokine designed to capture and expand the therapeutic benefits of high-dose recombinant human IL-2 while mitigating its hallmark toxicities.

Mural Oncology plc Management structure

All Gross Remunerations are in USD
Mr. Adam D. Cutler
Chief Financial Officer and Principal Accounting Officer
-
2024
Gross Remuneration
Year
Dr. Caroline Loew, PhD
Chief Executive Officer and Director
-
2024
Gross Remuneration
Year

Mural Oncology plc Board of directors

All Gross Remunerations are in USD
Dr. George S. Golumbeski, PhD
Independent Director
-
2024
Gross Remuneration
Year
Dr. Susan Altschuller, M.B.A.,PhD
Independent Director
-
2024
Gross Remuneration
Year
Ms. Sachiyo Minegishi, M.B.A.
Independent Director
-
2024
Gross Remuneration
Year
Mr. Scott T. Jackson, M.B.A.
Chairman of the Board
-
2024
Gross Remuneration
Year
Dr. Francis M. Cuss, F.R.C.P.,M.B.
Independent Director
-
2024
Gross Remuneration
Year
Mr. Benjamin J. Hickey, M.B.A.
Independent Director
-
2024
Gross Remuneration
Year

Mural Oncology plc FAQ

How is Mural Oncology plc today?
Mural Oncology plc today is trading in the red, and is down by -0.37% at 2.69.
Mural Oncology plc is currently trading down -0.37% on an intraday basis. In the past week the stock rose 161.17%. stock has been down -32.75% in the past quarter and fell -24.65% in the past year. You can view this in the overview section.